FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Cancer
Pembrolizumab has been approved by the FDA for the use in advanced microsatellite instability–high/mismatch repair–deficient endometrial cancer following prior systemic therapy.
David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
2 Clarke Drive Cranbury, NJ 08512